Posted by Michael Wonder on 31 Oct 2023
Phathom Pharmaceuticals announces FDA approval of reformulated vonoprazan tablets for Voquenza Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquenza Dual Pak (vonoprazan, amoxicillin) for the treatment of H. pylori infection in adults
30 October 2023 - Planning for a December 2023 US launch for H. pylori, together with the US launch of vonoprazan for Erosive GERD, if approved.
Phathom Pharmaceuticals announced that the US FDA has approved the prior approval supplement for the reformulation of vonoprazan tablets for both Voquenza Triple Pak (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and Voquenza Dual Pak (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults.
